Dr. Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL's new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.
|Headquarters||Door No 8-2-337|
Road No 3, Banjara Hills
HYDERABAD, India 500034
|Executive Chairman of the Board, Chief Executive Officer||G. Prasad|
|Executive Vice Chairman of the Board, Chief Operating Officer, Managing Director||Satish Reddy|
|Chief Financial Officer, President, Global Head - Quality, HR and IT||Saumen Chakraborty|
|President - Pharmaceutical Services and Active Ingredients||R. Ananthanarayanan|
|President - Global Generics||Abhijit Mukherjee|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||169.8M||Book Value||$6.17|
|Annual Dividend Rate||$0.25||Price/Sales (TTM)||3.2|
|Ex-Div Date||6/27/12||P/Cash Flow (TTM)||17.7x|
|Pay Date||6/27/13||Operating Margin||16.31%|
*GAAP = prior to non-GAAP analyst adjusted earnings.